<DOC>
	<DOCNO>NCT02090036</DOCNO>
	<brief_summary>The purpose study assess efficacy safety single low-dose Primaquine add standard artemether/lumefantrine treatment clearance Plasmodium falciparum gametocyte among patient uncomplicated malaria age 1 year regardless G6PD status .</brief_summary>
	<brief_title>Efficacy Safety Single Low-dose Primaquine Clearance Gametocytes</brief_title>
	<detailed_description>The current gained success malaria control accredit partly availability efficacious fast acting artemisinins also potent P. falciparum young gametocyte . Nonetheless , mature gametocyte may persist treatment , contribute malaria transmission . Conversely , artemisinin resistance confirm South-east Asia , may spread Africa . New control tool integrate sustain gain success , reduce transmission curb spread resistance . Primaquine strong gametocytocidal effect mature gametocytes added schizonticidal drug artemether-lumefantrine ( AL ) , rapidly shorten gametocyte carriage duration , halt disease transmission . Nonetheless , wide scale use hamper dose-dependent acute hemolytic anemia cause glucose-6-phosphate dehydrogenase ( G6PD ) deficient individual . Conversely , Artemisinins potentiate primaquine activity , thus low dose primaquine would able clear falciparum gametocyte . The World Health Organization recommend addition 0.25 mg/kg single-dose primaquine Artemisinin base combination therapy malaria endemic area include Africa without test G6PD status . Nonetheless , recommendation , rely historical data South-East Asia among African Americans United States . Therefore , study plan assess safety efficacy 0.25 mg/kg single-dose primaquine add standard AL treatment P. falciparum gametocyte clearance among patient uncomplicated malaria age 1 year regardless G6PD status..</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<criteria>Age 1 year neither pregnant breast feeding . Weight 10 kg . Body temperature ≥37.5°C ) history fever last 24 hour . P. falciparum monoinfection . Evidence severe illness malaria danger sign . Known allergy study medication . Hemoglobin &lt; 8 g/dl . Antimalarials take within last 2 week . Blood transfusion within last 90 day evidence recent use ( within 14 day ) take drug know cause hemolysis G6PD deficient subject .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Primaquine</keyword>
	<keyword>Artemether-lumefantrine</keyword>
	<keyword>Gametocytes</keyword>
</DOC>